125
Participants
Start Date
March 7, 2016
Primary Completion Date
July 23, 2022
Study Completion Date
November 3, 2023
brexucabtagene autoleucel
A single infusion of brexucabtagene autoleucel CAR transduced autologous T cells administered intravenously.
Cyclophosphamide
Administered intravenously.
Fludarabine
Administered intravenously.
Mount Sinai Tisch Cancer Institute, New York
Memorial Sloan-Kettering Cancer Center, New York
Institut Paoli Calmettes, Marseille
University of Rochester, New York
University of MD Greenbaum Comprehensive Cancer Center, Baltimore
Emory University, Atlanta
Hopital Haut-Leveque, Pessac
H Lee Moffitt Cancer Center, Tampa
Hopital Pontchaillou - CHU de Rennes - Service d'Hematologie, Rennes
Sarah Cannon, Nashville
Vanderbilt-Ingram Cancer Center, Nashville
Mayo Clinic, Rochester
Loyola University, Chicago
Universitatsklinikum Frankfurt, Frankfurt
University of Chicago, Chicago
Washington University School of Medicine, St Louis
Hopital Saint Louis, Paris
Baylor Charles A. Sammons Cancer Center, Dallas
University of Texas MD Anderson Cancer Center, Houston
Klinikum der Universitat Munchen, München
University of California Los Angeles (UCLA), Los Angeles
UC San Diego-Moores Cancer Center, La Jolla
University of California Irvine Medical Center, Orange
University of California San Francisco, San Francisco
University of California Davis Comprehensive Cancer Center, Sacramento
Universitaetsklinikum Wuerzburg, Würzburg
Swedish Cancer Institute, Seattle
Seattle Cancer Center, Seattle
Dana Farber Cancer Institute, Boston
University Health Network - Princess Margaret, Toronto
Amsterdam UMC, Amsterdam
Erasmus MC, Rotterdam
Universitair Medisch Centrum Utrecht, Utrecht
Kite, A Gilead Company
INDUSTRY